Herpes simplex vaccine comprising HSV glycoprotein GD and 3 deac

Details Herpes simplex vaccine comprising HSV glycoprotein GD and 3 deac Herpes simplex vaccine comprising HSV glycoprotein GD and 3 deac

1994-09-09

2000-02-22

Minnifield, Nita

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

4241841, 4242291, 4242261, 4241921, 4242021, 4242821, 4242271, 4242311, 4242081, 424690, 424698, 424486, 424499, 514 12, 514 4, 514 8, 530350, A61K 39245, A61K 4500, A61K 916, A01N 5906

Patent

active

060277300

ABSTRACT:
Novel herpes simplex (HSV) vaccine formulations are provided. These comprise HSV glycoprotein gD or immunological fragments in conjunction with 3 Deacylated monophosphoryl lipid A.

REFERENCES:
patent: 4372945 (1983-02-01), Likhite
patent: 4474757 (1984-10-01), Arnon et al.
patent: 4762708 (1988-08-01), Cohen et al.
patent: 4877611 (1989-10-01), Cantrell
patent: 4912094 (1990-03-01), Myers et al.
patent: 5110587 (1992-05-01), Paolett et al.
patent: 5149529 (1992-09-01), Ho et al.
patent: 5149660 (1992-09-01), Cohen et al.
patent: 5158939 (1992-10-01), Takayama
patent: 5166173 (1992-11-01), Hwang et al.
patent: 5171568 (1992-12-01), Burke et al.
patent: 5196452 (1993-03-01), Hwang et al.
patent: 5244792 (1993-09-01), Burke et al.
patent: 5334379 (1994-08-01), Pillai et al.
patent: 5470718 (1995-11-01), O'Callaghan
patent: 5554372 (1996-09-01), Hunter
patent: 5597573 (1997-01-01), Kamireddy et al.
patent: 5650152 (1997-07-01), Anderson et al.
patent: 5723130 (1998-03-01), Hancock et al.
patent: 5750110 (1998-05-01), Prieels et al.
patent: 5750114 (1998-05-01), Burke et al.
patent: 5776468 (1998-07-01), Hauser et al.
patent: 5795579 (1998-08-01), Burke et al.
L. Sanchez-Pescador et al., A Comparison of Adjuvant Efficacy for a Recombinant Herpes Simplex Virus Glycoprotein Vaccine (1988), Tech. Advances in Vac. Develop., p. 455-469.
Lawrence R. Stanberry et al., Herpes Simplex Virus Glycoprotein Immunotherapy of Recurrent Gentil Herpes: Factors Influencing Efficacy, Antiviral Research 11, 1989, p. 203-214.
Rhoda Ashley et al., Humoral Immune Response to Herpes Simplex Virus Type 2 . . . , J. Virology 56, 1985, p. 475-481.
Kent R. Myers et al., A Critical Determinant of Lipid A Endotoxic Activity, pp. 145-156 in Excerpta Medic, 1990, Novotny et al. Eds.
Vogel et al. In: Vaccine Design ed. Powell et al pp. 2-92, 1994.
Bomford, Rev. in Medical Virology; 2:169-174, 1992.
Schultz et al Vaccine 13/5:503-508, 1995.
Sanchez-Pescador et al J. Immunology 141:1720-1727, 1988.
Schneerson et al, J. Immunology 147:2136-2140, 1991.
Long et al. Infect. Imm. 37(2):761-764, Feb. 1984.
Cremer et al. Vaccinia Viruses as Vectors For Vaccine Antigens. Ed:Quinnan pp. 153-161, 1985.
Ghiasi et al. Antiviral Research. 28:147-157, 1995.
Berman et al, Herpesvirus 21:637-49 UCLA Symp Mol. Cell. Biol, New Series, 1984.
Schneerson et al, J Immunol, 147(7):2316-40, Oct. 1991.
Drew et al, 1992, J. Gen. Virol. 73:2357-66.
Langenberg et al, 1995, Annals Internal Med. 122(12):889-898.
Hazama et al, 1993, Immunology 78:643-648.
Geerligs et al, 1989, J. Immunol. Methods, 124:95-102.
Sanchez-Pescader et al, 1988, J. Immunol. 141(5):1720-27.
Naylor et al, 1982, Inf. & Imm. 36(3):1209-1216.
Zarlings et al, 1986, J. Immunol., 136(12):4669-4673.
Eisenberg et al, 1985. J. Virol. 56(3):1014-17.
Berman et al, 1988, J Infect Dis. 157(5):897-902.
Lasky et al, 1984. Bio/Technology, 2/6:527-532.
Weis et al, 1983, Nature, 302(3):72-74.
Brynestad et al, 1990, J. Virol. 64(2):680-685.
Mertz et al, 1990, J. Infect. Dis. 161:653-660.
Stanberry et al, 1987, J. Infect. Dis. 155(5):914-920.
Plotkin et al, 1988. Vaccines, pp. 568-575. WB Saunders Co.
Burke, 1991, J. Inf. Dis. 13(Supp 11):S906-11.
Rooney et al, 1991, J. Infect. Dis. 13(Suppl 11):S898-903.
Pass. 1988. J. Am. Acad. Dermatol. 18:224-6.
Berman 1988. J. Am Acad Dermatol. 18:226-30.

Affiliated with

Also associated with

Rating

Herpes simplex vaccine comprising HSV glycoprotein GD and 3 deac does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Herpes simplex vaccine comprising HSV glycoprotein GD and 3 deac, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Herpes simplex vaccine comprising HSV glycoprotein GD and 3 deac will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-518208